文献速递慢性肾脏病肾小球疾病

新检出白蛋白尿的诊疗流程与临床响应:SCREAM项目

Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) Project.
PubMed 文献 · Am J Kidney Dis · 2025-12-06

该回顾性人群队列研究纳入瑞典斯德哥尔摩2010至2021年间215,035例新检出白蛋白尿的成人,评估了复检率、肾内科转诊率及肾素-血管紧张素系统或SGLT2抑制剂启动率。结果显示1年内复检率仅46%,有指征者转诊率28%,治疗启动率在中度、重度、极重度白蛋白尿中分别为10%、12%、37%,无糖尿病者更低。研究揭示了白蛋白尿管理中的显著诊疗差距。

要点

  • 新检出白蛋白尿患者1年内复检率仅46%,极重度者70%,无糖尿病者更低。
  • 有转诊指征者仅28%转诊至肾内科。
  • 1年内RAS或SGLT2抑制剂启动率中度10%、重度12%、极重度37%,无糖尿病者显著更低。

核心结论

  • 瑞典白蛋白尿管理存在显著诊疗差距,包括监测不足和抗蛋白尿治疗启动率低。

研究设计与样本

  • 回顾性人群队列研究,纳入2010至2021年瑞典斯德哥尔摩215,035例新检出白蛋白尿的成人。

主要发现

  • 90%为中度白蛋白尿,8%为重度,2%为极重度。
  • 1年内复检率为46%,中度45%,极重度70%,无糖尿病者更低。
  • 有指征者仅28%转诊肾内科。
  • 1年内RAS或SGLT2抑制剂启动率中度10%、重度12%、极重度37%,无糖尿病者显著更低。

关键数值与推荐

  • 白蛋白尿分级:中度≥30-299 mg/g,重度300-999 mg/g,极重度≥1000 mg/g。

临床怎么用

  • 应加强新检出白蛋白尿患者的复检、肾内科转诊及肾脏保护药物启动。

局限性

  • 结果仅适用于斯德哥尔摩医疗体系,可能无法推广至其他地区、医疗模式或文化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Albuminuria is a predictor of adverse health outcomes. Early detection enables timely clinical management, yet little is known about how clinicians respond to newly detected albuminuria in routine practice. This study characterized clinical care processes for patients with newly detected albuminuria. STUDY DESIGN: Retrospective, population-based cohort study. SETTING & PARTICIPANTS: 215,035 adults with newly detected albuminuria between 2010 and 2021 in Stockholm, Sweden. EXPOSURE: Albuminuria severity, categorized as moderate (≥30-299 mg/g), severe (300-999 mg/g), or very severe (≥1000 mg/g). All methods of albuminuria testing were considered: dipstick albuminuria or proteinuria tests as well as 24-hour and spot albumin concentrations. OUTCOME: Proportion of patients retested for albuminuria, frequency of the methods used for retesting, rates of nephrology referral, and rates of initiation of treatment with renin angiotensin system or sodium/glucose cotransporter 2 inhibitors. ANALYTICAL APPROACH: Descriptive analysis of proportions and cumulative incidence of outcomes based on time-to-event analysis accounting for the competing risks of death and kidney failure. RESULTS: We found 90% of participants had moderate, 8% had severe, and 2% had very severe albuminuria. Retesting rates within 1 year were 46%, ranging from 45% for moderate albuminuria to 70% for very severe albuminuria, with lower rates among individuals without diabetes. Only 28% of those with an indication were referred to a nephrologist, and renin angiotensin system and sodium/glucose cotransporter 2 inhibitor initiation rates at 1 year were 10%, 12%, and 37% for moderate, severe, and very severe albuminuria, respectively, with substantially lower rates in individuals without diabetes. LIMITATIONS: The findings are specific to Stockholm's health care system and may not be generalizable to other regions, health care models, or cultures. CONCLUSIONS: This study identified important care gaps in the Swedish management of albuminuria. A substantial proportion of individuals, including those with very severe albuminuria, lacked monitoring and failed to receive antiproteinuric treatments. Strategies to improve clinician awareness and adherence to guideline-recommended care may mitigate the long-term consequences of chronic kidney disease progression. PLAIN-LANGUAGE SUMMARY: Early signs of kidney damage, such as albuminuria (protein in the urine) may not always lead to the appropriate clinical follow-up that is recommended in clinical practice guidelines. This study characterized how patients with albuminuria were managed in Stockholm's health care environment. Between 2010 and 2021, 215,035 adults had elevated albuminuria detected for the first time, but many did not receive the recommended follow-up care, including a confirmation test, referral to a nephrologist when indicated, or initiation of kidney-protective medications. This study highlights the need for better strategies to improve care for individuals with albuminuria, ensuring earlier intervention that may prevent more severe health consequences of early indications of kidney damage.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Créon A, Faucon AL, Caldinelli A, et al. Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) Project. Am J Kidney Dis. 2025. PMID: 41360255. doi:10.1053/j.ajkd.2025.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。